Amylin and Bristol-Myers Squibb won't comment on reports that Amylin rejected $3.5 billion offer
This article was originally published in Scrip
Executive Summary
Neither Bristol-Myers Squibb nor Amylin Pharmaceuticals would confirm reports that the pharmaceutical giant made a $3.5 billion unsolicited offer to buy the San Diego biotechnology company, but such a transaction could be beneficial for both firms.